The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Renziehausen, A., Wang, H., Rao, B., Weir, L., Nigro, C. L., Lattanzio, L., Merlano, M., Vega-Rioja, A., Del Carmen Fernandez-Carranco, M., Hajji, N., Matin, R., Harwood, C., Li, S., Sim, V. R., O'Neill, K., Evans, A., Thompson, A., Szlosarek, P., Fleming, C., Stebbing, J., Proby, C., Tzakos, A. G., Syed, N., & Crook, T. Oncogene, 38(13):2320–2336, March, 2019.
The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention [link]Paper  doi  abstract   bibtex   
Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic versus primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.
@article{renziehausen_renin_2019,
	title = {The renin angiotensin system ({RAS}) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention},
	volume = {38},
	copyright = {All rights reserved},
	issn = {1476-5594 (Electronic) 0950-9232 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30478450},
	doi = {10.1038/s41388-018-0563-y},
	abstract = {Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic versus primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.},
	number = {13},
	journal = {Oncogene},
	author = {Renziehausen, A. and Wang, H. and Rao, B. and Weir, L. and Nigro, C. L. and Lattanzio, L. and Merlano, M. and Vega-Rioja, A. and Del Carmen Fernandez-Carranco, M. and Hajji, N. and Matin, R. and Harwood, C. and Li, S. and Sim, V. R. and O'Neill, K. and Evans, A. and Thompson, A. and Szlosarek, P. and Fleming, C. and Stebbing, J. and Proby, C. and Tzakos, A. G. and Syed, N. and Crook, T.},
	month = mar,
	year = {2019},
	pages = {2320--2336},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021